# US 8,278,454 B2 · Process for preparing tetrahydroquinoline derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,454 B2
- Document ID: US8278454B2
- Status: Granted
- Kind: B2
- Application number: 12/808,819
- Filed: 2008-11-20
- Published: 2010-12-09
- Granted: 2012-10-02
- Earliest claimed: 2007-12-18
- Assignees: Merck Patent GmbH
- Inventors: Ulrich Emde; Oliver Block; Kai Schiemann
- Web page: https://patentgrep.com/patent/US8278454B2

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.

## Claims

### Claim 1

A process for the manufacture of an enantiomerically enriched or pure compound of formula I:
wherein
Ra denotes Hal, cyano, COOH, COOA, A, CF3;
R1 denotes H, A, Ar, Het, Hal, —(CY2)n—SA, —(CY2)n—SCF3, —(CY2)n—SCN, —(CY2)n—CF3, —(CY2)n—OCF3, R, cycloalkyl, —SCH3, —SCN, —CF3, —OCF3, —OA, —(CY2)n—OH, —(CY2)n—CO2R, —(CY2)n—CN, —(CY2)n-Hal, —(CY2)n—NR2, (CY2)n—OA, (CY2)n—OCOA, —SCF3, (CY2)n—CONR2, —(CY2)n—NHCOA, —(CY2)n—NHSO2A, SF5, Si(CH3)3, CO—(CY2)n—CH3, —(CY2)n—N-Pyrrolidone, (CH2)nNRCOOR, NRCOOR, NCO, (CH2)nCOOR, NCOOR, (CH2)nOH, NR(CH2)nNR2, C(OH)R2, NR(CH2)nOR, NCOR, (CH2)nAr, (CH2)nHet, (CH2)nR, (CH2)nX(CH2)nAr, (CH2)nX(CH2)nHet, (CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nXAr, N[(CH2)nXR]SO2(CH2)nAr, N[(CH2)nNRCOOR]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nNRAr, N[(CH2)nNR2]SO2(CH2)nAr, N[(CH2)nXR]CO(CH2)nHet, N[(CH2)nXR]CO(CH2)nXHet, N[(CH2)nXR]SO2(CH2)nHet, N[(CH2)nNRCOOR]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nNRHet;
R2, R3 denotes H, A, Hal, OA, OR;
Y denotes H, A, Hal, OR;
A denotes Alkyl or Cycloalkyl, wherein one or more H-atoms can be replaced by Hal;
Hal denotes F, Cl, Br or I;
R denotes H or A, in the case of geminal groups R together also —(CH2)5—, —(CH2)4— or —(CH2)n—X—(CH2)n, or —(CH2)n—Z—(CH2)n;
X denotes O, S, NA or NH;
Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1;
Z denotes CH2, X, CHCONH2, CH(CH2)nNRCOOR, CHNRCOOR, NCHO, CHCON(R)2, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, NCOR, N(CH2)nAr, N(CH2)nHet, CHR, NR, CH(CH2)nAr, CH(CH2)nHet, CH(CH2)nR, N(CH2)nCOOR, CH(CH2)nX(CH2)nAr, CH(CH2)nX(CH2)nHet, N(CH2)nCON(R)2, NSO2R, CHSO2N(R)2, XCONR(CH2)nN(R)2, NCO(CH2)nAr, NCO(CH2)nXAr, NSO2(CH2)nAr, NCO(CH2)nAr, NCO(CH2)nNRAr, NCO(CH2)nHet, NCO(CH2)nXHet, NSO2(CH2)nHet, NCO(CH2)nNRHet, N(CH2)nNR2CH, CHO(CH2)nN(R)2, CHX(CH2)nN(R)2, or, NCO(CH2)nNR2;
R6 denotes unsubstituted Ar or Het which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Ar or Het which also may be substituted by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2,
R7 denotes (C═O)—R, (C═O)—NR2, (C═O)—OR, H or A;
Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2;
Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)nCO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2;
n denotes 0, 1, 2, 3, 4, 5, 6 or 7;
or a pharmaceutically acceptable tautomer or salt thereof, said process comprising:
reacting an aniline compound A and an aldehyde B
with a chiral dihydropyran methylamine compound C
in the presence of a suitable solvent and a protonic acid or Lewis acid wherein R1 to R6 and Q are as described above.

### Claim 2 (depends on 1)

The process according to claim 1, wherein Q is —CH2—NH(CO)R, —CH2—NHSO2R or CH2NH-A.

### Claim 3 (depends on 1)

The process according to claim 1, wherein Q is CH2NH—CH3, CH2NH—C(O)NH(CH2)2N(CH3)2.

### Claim 4 (depends on 1)

The process according to claim 1, wherein R6 is an unsubstituted Ar.

### Claim 5 (depends on 1)

The process according to claim 1, wherein R3 is H.

### Claim 6 (depends on 1)

The process according to claim 1, wherein R2 is H.

### Claim 7 (depends on 1)

The process according to claim 1, wherein Ra is A.

### Claim 8 (depends on 1)

The process according to claim 1, wherein Ra is CF3 and R7 is H.

### Claim 9 (depends on 1)

The process according to claim 1, wherein the protonic acid is trifluoroacetic acid.

### Claim 10 (depends on 9)

The process according to claim 9, wherein the solvent is acetonitrile.

### Claim 11 (depends on 1)

The process according to claim 1, wherein Q is —CH2—NHCH3, Ra is Cl, R2 is F, R3 is H, R7 is H and R6 is unsubstituted Ar.

### Claim 12

A process for the manufacture of enantiomerically enriched or pure compounds of formula C:
wherein
Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1,
R1 denotes H, A, Ar, Het, Hal, —(CY2)n—SA, —(CY2)n—SCF3, —(CY2)n—SCN, —(CY2)n—CF3, —(CY2)n—OCF3, R, cycloalkyl, —SCH3, —SCN, —CF3—OCF3, —OA, —(CY2)n—OH, —(CY2)n—CO2R, —(CY2)n—CN, —(CY2)n-Hal, —(CY2)n—NR2, (CY2)n—OA, (CY2)n—OCOA, —SCF3, (CY2)n—CONR2, —(CY2)n—NHCOA, —(CY2)n—NHSO2A, SF5, Si(CH3)3, CO—(CY2)n—CH3, —(CY2)n—N-Pyrrolidone, (CH2)nNRCOOR, NRCOOR, NCO, (CH2)nCOOR, NCOOR, (CH2)nOH, NR(CH2)nNR2, C(OH)R2, NR(CH2)nOR, NCOR, (CH2)nAr, (CH2)nHet, (CH2)nR, (CH2)nX(CH2)nAr, (CH2)nX(CH2)nHet, (CH2)nCONR2, XCONR(CH2)nNR2, N[(CH2)nXCOOR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nAr, N[(CH2)nXR]CO(CH2)nXAr, N[(CH2)nXR]SO2(CH2)nAr, N[(CH2)nNRCOOR]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nAr, N[(CH2)nNR2]CO(CH2)nNRAr, N[(CH2)nNR2]SO2(CH2)nAr, N[(CH2)nXR]CO(CH2)nHet, N[(CH2)nXR]CO(CH2)nXHet, N[(CH2)nXR]SO2(CH2)nHet, N[(CH2)nNRCOOR]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nHet, N[(CH2)nNR2]CO(CH2)nNRHet,
Y denotes H, A, Hal, or OR,
A denotes Alkyl or Cycloalkyl, wherein one or more H-atoms can be replaced by Hal
Hal denotes F, Cl, Br or I,
R denotes H or A, in the case of geminal groups R together also —(CH2)5—, —(CH2)4— or —(CH2)n—X—(CH2)n, or —(CH2)n—Z—(CH2)n,
X denotes O, S, NH or NA,
Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1,
Z denotes CH2, X, CHCONH2, CH(CH2)nNRCOOR, CHNRCOOR, NCHO, CHCON(R)2, CH(CH2)nCOOR, NCOOR, CH(CH2)nOH, N(CH2)nOH, CHNH2, CH(CH2)nNR2, CH(CH2)nNR2, C(OH)R, CHNCOR, NCOR, N(CH2)nAr, N(CH2)nHet, CHR, NR, CH(CH2)nAr, CH(CH(CH2)nHet, CH(CH2)nR, N(CH2)nCOOR, CH(CH2)nX(CH2)nAr, CH(CH2)nX(CH2)nHet, N(CH2)nCON(R)2, NSO2R, CHSO2N(R)2, XCONR(CH2)nN(R)2, NCO(CH2)nAr, NCO(CH2)nXAr, NSO2(CH2)nAr, NCO(CH2)nAr, NCO(CH2)nNRAr, NCO(CH2)nHet, NCO(CH2)nXHet, NSO2(CH2)nHet, NCO(CH2)nNRHet, N(CH2)nNR2CH, CHO(CH2)nN(R)2, CHX(CH2)nN(R)2, NCO(CH2)nNR2,
Ar denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms which may be unsubstituted which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2,
Het denotes a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms which may be unsubstituted or which is substituted in at least one position by Hal, NO2, CN, OR, A, —(CY2)n—OR, —OCOR, —(CY2)n—CO2R, —(CY2)n—CN, —NCOR, —COR or —(CY2)n—NR2 or by Hal, NO2, CN, A, OR, OCOR, COR, NR2, CF3, OCF3, OCH(CF3)2, and
n denotes 0, 1, 2, 3, 4, 5, 6 or 7,
as well as their pharmaceutically acceptable tautomers and salts,
said process comprising:
A)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give enantiomerically enriched or pure dihydropyran methylamine salts;
and optionally using a base to obtain the free base from the dihydropyran methylamine salts;
or
B)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
reacting the resulting compound with ClC(O)R1 or ClSO2R1 in the presence of a non nucleophilic base in a polar solvent;
or
C)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
reacting the resulting compound with a primary amine NH2R1 with CDI in a solvent.

### Claim 13 (depends on 12)

The process according to claim 12 for the manufacture of enantiomerically enriched or pure compounds of formula C:
wherein Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1, as well as their pharmaceutically acceptable tautomers and salts, said process comprising:
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
reacting the resulting compound with ClC(O)R1 or ClSO2R1 in the presence of a non nucleophilic base in a polar solvent.

### Claim 14 (depends on 12)

The process according to claim 12 for the manufacture of enantiomerically enriched or pure compounds of formula C:
wherein Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1, as well as their pharmaceutically acceptable tautomers and salts, said process comprising:
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts, and
reacting the resulting compound with a primary amine NH2R1 with CDI in a solvent.

### Claim 15 (depends on 12)

The process according to claim 12, wherein
(a) Q is CH2NHMe, the chiral acid compound is L-tosylproline, the polar solvent ethanol and the base is NaOH; or
(b) Q is CH2NH2, and the chiral acid compound is (2R,3R)-(−)-Di-O-benzoyl tartaric acid.

### Claim 16 (depends on 13)

The process according to claim 13, wherein R1 is methyl, the chiral acid compound is L-tosylproline, the polar solvent ethanol, the base is NaOH and non nucleophilic base is triethylamine TEA.

### Claim 17 (depends on 14)

The process according to claim 14, wherein R1 is CH2—CH2—N(CH3)2, the chiral acid compound is L-tosylproline, the polar solvent ethanol, the base is NaOH, the coupling agent is 1,1′-carbonyldiimidazole and the solvent is CH2Cl2.

### Claim 18 (depends on 1)

The process according to claim 1, wherein separation of the exo and endo compounds obtained, is achieved by recrystallization with chiral salts or acid.

### Claim 19 (depends on 1)

The process according to claim 1, wherein compound C is obtained by
A)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give enantiomerically enriched or pure dihydropyran methylamine salts; and
optionally using a base to obtain the free base from the dihydropyran methylamine salts;
or
B)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts,
and reacting the resulting compound with ClC(O)R1 or ClSO2R1 in the presence of a non nucleophilic base in a polar solvent;
or
C)
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give the enantiomerically enriched or pure dihydropyran methylamine salts;
optionally using a base to obtain the free base from the dihydropyran methylamine salts,
and reacting the resulting compound with a primary amine NH2R1 with 1,1′-carbonyldiimidazole in a solvent.

### Claim 20 (depends on 1)

The process according to claim 1, wherein said compound of formula I is a compound of formula Ia2 or formula Ib2
or a pharmaceutically acceptable tautomer or salt thereof.

### Claim 21 (depends on 20)

The process according to claim 20, wherein enantiomerically enriched or pure compounds of formula Ia2 are obtained by recrystallization with (2R,3R)-(−)-Di-O-benzoyl tartaric acid salt in EtOH.

### Claim 22 (depends on 20)

The process according to claim 20, wherein enantiomerically enriched or pure compounds of formula Ib2 are obtained by recrystallization with HCl in EtOH.

### Claim 23 (depends on 12)

The process according to claim 12 for the manufacture of enantiomerically enriched or pure compounds of formula C:
wherein
Q denotes CH2—NH-A, CH2—NH—C(O)R1, CH2—NH—SO2R1, as well as their pharmaceutically acceptable tautomers and salts, said process comprising:
treating the racemic compound C, wherein Q is CH2NH2 or CH2NHA, with a chiral acid compound in a polar solvent to give enantiomerically enriched or pure dihydropyran methylamine salts;
and optionally using a base to obtain the free base from the dihydropyran methylamine salts.
